Skip to content
Screener

Reported November 12, 2026 · After market close

EPS-$0.42Beat by $0.02
Revenue estimate$504.3K
EPS estimate-$0.44
“I&I is particularly well-suited for our AP3 precision medicine approach. We acquired ACR-525 after identifying it as a potentially best-in-class JAK1 inhibitor using our AI-driven AP3 platform for extensive profiling head-to-head against approved JAK inhibitors and dupilumab. Based on this, eosinophilic esophagitis is targeted as an attractive first indication for this Phase 2-ready, oral, highly selective JAK1 inhibitor. The transaction also included a differentiated preclinical PKCθ program for T-cell driven I&I disorders. Additionally, we remain on track for the prespecified interim analysis of the ACR-368 Phase 2 registrational-intent trial. For ACR-2316, our highly differentiated, first-in-class WEE1/PKMYT1 inhibitor in Phase 1/2 dose expansion, we have observed a very favorable safety profile and exceptionally long-lasting clinical benefit across AP3 predicted tumors already during dose escalation. Of note, these include heavily pretreated lung cancers where several patients are on treatment for over 73 weeks now, and where we also have a confirmed complete response. Details of these exciting data will be presented by Dr. Tim Yap as a late-breaking oral plenary presentation at the upcoming Tri-Meeting. ACR-2316 will also be tested as single agent in pancreatic ductal adenocarcinoma based on public data showing WEE1 is synthetic lethal in K-Ras & p53 mutated context. Similar to ACR-368, we have shown that ACR-2316 has strong synergy with immune checkpoint inhibitors and Topo1 inhibitors, providing for attractive combination opportunities. Finally, we also nominated a potential first-in-class, oral CDK11 inhibitor, ACR-7280, identified through the AP3 platform, to advance into IND-enabling studies and be developed in the AP3-predicted tumor type AML.”
Peter Blume-Jensen

Next report

Date not yet announced

FAQ

When did Acrivon Therapeutics, Inc. report Q3 2026 earnings?
Acrivon Therapeutics, Inc. (ACRV) reported Q3 2026 earnings on November 12, 2026 after market close.
What were Acrivon Therapeutics, Inc.'s Q3 2026 revenue and EPS?
Acrivon Therapeutics, Inc. reported eps of $-0.42 for Q3 2026.
Did Acrivon Therapeutics, Inc. beat estimates in Q3 2026?
EPS beat the consensus estimate of $-0.44 by $0.02.
How did Acrivon Therapeutics, Inc.'s Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 10.6% from $-0.47.
Where can I find Acrivon Therapeutics, Inc.'s Q3 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-455669) and the 10-Q periodic report (0001193125-26-463419) directly on SEC EDGAR. The filing index links above go to sec.gov.